The Solar Orbiter EUI instrument: The Extreme Ultraviolet Imager (Corrigendum)

Autor: P. Rochus, F. Auchère, D. Berghmans, L. Harra, W. Schmutz, U. Schühle, P. Addison, T. Appourchaux, R. Aznar Cuadrado, D. Baker, J. Barbay, D. Bates, A. BenMoussa, M. Bergmann, C. Beurthe, B. Borgo, K. Bonte, M. Bouzit, L. Bradley, V. Büchel, E. Buchlin, J. Büchner, F. Cabé, L. Cadiergues, M. Chaigneau, B. Chares, C. Choque Cortez, P. Coker, M. Condamin, S. Coumar, W. Curdt, J. Cutler, D. Davies, G. Davison, J.-M. Defise, G. Del Zanna, F. Delmotte, V. Delouille, L. Dolla, C. Dumesnil, F. Dürig, R. Enge, S. François, J.-J. Fourmond, J.-M. Gillis, B. Giordanengo, S. Gissot, L. M. Green, N. Guerreiro, A. Guilbaud, M. Gyo, M. Haberreiter, A. Hafiz, M. Hailey, J.-P. Halain, J. Hansotte, C. Hecquet, K. Heerlein, M.-L. Hellin, S. Hemsley, A. Hermans, V. Hervier, J.-F. Hochedez, Y. Houbrechts, K. Ihsan, L. Jacques, A. Jérôme, J. Jones, M. Kahle, T. Kennedy, M. Klaproth, M. Kolleck, S. Koller, E. Kotsialos, E. Kraaikamp, P. Langer, A. Lawrenson, J.-C. Le Clech’, C. Lenaerts, S. Liebecq, D. Linder, D. M. Long, B. Mampaey, D. Markiewicz-Innes, B. Marquet, E. Marsch, S. Matthews, E. Mazy, A. Mazzoli, S. Meining, E. Meltchakov, R. Mercier, S. Meyer, M. Monecke, F. Monfort, G. Morinaud, F. Moron, L. Mountney, R. Müller, B. Nicula, S. Parenti, H. Peter, D. Pfiffner, A. Philippon, I. Phillips, J.-Y. Plesseria, E. Pylyser, F. Rabecki, M.-F. Ravet-Krill, J. Rebellato, E. Renotte, L. Rodriguez, S. Roose, J. Rosin, L. Rossi, P. Roth, F. Rouesnel, M. Roulliay, A. Rousseau, K. Ruane, J. Scanlan, P. Schlatter, D. B. Seaton, K. Silliman, S. Smit, P. J. Smith, S. K. Solanki, M. Spescha, A. Spencer, K. Stegen, Y. Stockman, N. Szwec, C. Tamiatto, J. Tandy, L. Teriaca, C. Theobald, I. Tychon, L. van Driel-Gesztelyi, C. Verbeeck, J.-C. Vial, S. Werner, M. J. West, D. Westwood, T. Wiegelmann, G. Willis, B. Winter, A. Zerr, X. Zhang, A. N. Zhukov

Publikováno v: Astronomy & Astrophysics. 665:C1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d55400524d23bed4ba9a7455d1d9cc2
https://doi.org/10.1051/0004-6361/201936663e

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Autor: Richardson, P.G. Oriol, A. Beksac, M. Liberati, A.M. Galli, M. Schjesvold, F. Lindsay, J. Weisel, K. White, D. Facon, T. San Miguel, J. Sunami, K. O'Gorman, P. Sonneveld, P. Robak, P. Semochkin, S. Schey, S. Yu, X. Doerr, T. Bensmaine, A. Biyukov, T. Peluso, T. Zaki, M. Anderson, K. Dimopoulos, M. Abildgaard, N. Adler, H. Altuntas, F. Akay, O.M. Amin, B. Anagnostopoulos, A. Anderson, L. Anttila, P. Araujo, C. Arce-Lara, C. Aydin, Y. Basu, S. Battini, R. Beeker, T. Benboubker, L. Ben-Yehuda, D. Bladé, J. Blau, I.W. Boccia, R. Burke, L. Byeff, P. Cascavilla, N. Cavo, M. Chantry, A. Charles, Y. Chaudhry, A. Corso, A. Coyne, M. De Arriba, F. Delimpasi, S. Desjardins, P. Dhakal, B. Di Bartolomeo, P. Di Raimondo, F. Dürig, J. Engelhardt, M. Escoffre-Barbe, M. Esteves, G. Flogegard, M. Gabrail, N. Gamberi, B. Garrison, M. Gay, J. Gisslinger, H. Goldschmidt, H. Goncalves, C. Gressot, L. Grosicki, S. Hanna, W. Hayden, P. Henriques Bernardo, M.M. Hermann, R. Holden, V. Honkalehto, K. Huben, M. Huffman, J. Hunter, H. Hus, M. Jagasia, M. Jagganath, S. Janakiram, M. Jaiyesimi, I. Jenner, M. João, C. Johnson, P. Jurcyszyn, A. Kalayoğlu Beşişik, S. Kambhampati, S. Kanate, A. Karadoğan, I. Khojasteh, A. Kirkel, D. Komarnicki, M. Krauth, M.-T. Kuriakose, P. Larocca, A. Lauri, B. Leleu, X. Lucio, P. Luppi, M. Mangiacavalli, S. Mariette, C. Matsue, K. Mellqvist, U.-H. Mendeleeva, L. Meshad, M. Miller, C. Mohrbacher, A. Moreau, P. Morelli, A.M. Müldür, E. Naassan, A. Nahi, H. Nair, R. O'Dwyer, M. Öngören Aydin, S. Openshaw, T. O'Rourke, T. Osswald, M. Overton, L. Pati, A. Pavic, M. Pegourie, B. Pehlivan, M. Pierola, A.A. Plesner, T. Pluta, A. Rabin, N. Ramasamy, K. Rambaldi, A. Rodriguez, P. Röllig, C. Rosenblatt, J. Rosenbluth, J. Salomo, M. Samoylova, O. Sastre Moral, J. Sati, H. Selleri, C. Shafeek, S. Shinagawa, A. Sleckman, B. Smith, C. Sonmez, M. Stone, C. Streetly, M. Suzuki, K. Taetle, R. Tafuri, A. Takezako, N. Teke, H.Ü. Vapaatalo, M. Vassilopoulos, G. Verma, A. Vidito, S. Viterbo, L. Vural, F. Wang, X.S. Yağci, M. Yee, A. OPTIMISMM trial investigators

Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has sho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::60a64e8be607a2d94110070c4a87c17f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3122238

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Autor: Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A.

Publikováno v: LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BASE-Bielefeld Academic Search Engine
Lancet Oncology, 20(6), 781-794. Lancet Publishing Group
Richardson, P G, Oriol, A, Beksac, M, Liberati, A M, Galli, M, Schjesvold, F, Lindsay, J, Weisel, K, White, D, Facon, T, San Miguel, J, Sunami, K, O'Gorman, P, Sonneveld, P, Robak, P, Semochkin, S, Schey, S, Yu, X, Doerr, T, Bensmaine, A, Biyukov, T, Peluso, T, Zaki, M, Anderson, K, Dimopoulos, M, OPTIMISMM trial investigators & Abildgaard, N 2019, ' Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 6, pp. 781-794 . https://doi.org/10.1016/S1470-2045(19)30152-4

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has show

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cccf2220a5bc187bbb4a4254d3d0f52
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4189